MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 642-648

  Liu, Dongxiao ^a   Sun, Qingmin ^b   Liang, Song ^c   Xu, Linlin ^d   Luo, Xuan ^d   Zhao, Xiaomei ^d   Wang, Xuerong ^d   Yang, Li ^c  

^a Nanjing Second Hospital   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Combination therapy; Gastric cancer; MicroRNA 27a; Perifosine

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 27A; MICRORNA 27A INHIBITOR; PERIFOSINE; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLCHOLINE; STOMACH NEOPLASMS;

EID: 84873844785     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1191     Document Type: Article

References (31)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Erratum: estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 870-873, 1999.
2. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ and Ezzati M: Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366: 1784-1793, 2005.
3. Orditura M, De Vita F, Muto P, et al: Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg 145: 233-238, 2010.
4. Milne AN, Carneiro F, O'Morain C and Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 126: 615-628, 2009.
5. Dykxhoorn DM: MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 70: 6401-6406, 2010.
6. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
7. Yang H, Kong W, He L, et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433, 2008.
8. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111: 478-486, 2008.
9. Zhu H, Wu H, Liu X, et al: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76: 582-588, 2008.
10. Mertens-Talcott SU, Chintharlapalli S, Li X and Safe S: The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2 M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 67: 11001-11011, 2007.
11. Pathi SS, Jutooru I, Chadalapaka G, et al: GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA- 27a: ZBTB10-specificity protein pathway. Mol Cancer Res 9: 195-202, 2011.
12. Liu T, Tang H, Lang Y, Liu M and Li X: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 273: 233-242, 2009.
13. Sun Q, Cong R, Yan H, et al: Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol Rep 22: 563-567, 2009.
14. Zhao X, Yang L and Hu J: Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 30: 55, 2011.
15. Zhang H, Li M, Han Y, et al: Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 55: 2545-2551, 2010.
16. Li Z, Hu S, Wang J, et al: MiR-27a modulates MDR1/P glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 119: 125-130, 2010.
17. Feng DD, Zhang H, Zhang P, et al: Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med 15: 2164-2175, 2011.
18. Vink SR, Schellens JH, van Blitterswijk WJ and Verheij M: Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 23: 279-286, 2005.
19. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B and Engel J: D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33: 442-446, 1997.
20. Nyakern M, Cappellini A, Mantovani I and Martelli AM: Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 5: 1559-1570, 2006.
21. Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA and Roy KK: Invitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 10: 5242-5252, 2004.
22. Van Ummersen L, Binger K, Volkman J, et al: A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10: 7450-7456, 2004.
23. Richardson PG, Wolf J, Jakubowiak A, et al: Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 29: 4243-4249, 2011.
24. Papazisis KT, Geromichalos GD, Dimitriadis KA and Kortsaris AH: Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 208: 151-158, 1997.
25. Ueda T, Volinia S, Okumura H, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 11: 136-146, 2010.
26. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F and Orditura M: Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 36 Suppl 3: S11-S15, 2010.
27. Ruan K, Fang X and Ouyang G: MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285: 116-126, 2009.
28. Mirnezami AH, Pickard K, Zhang L, Primrose JN and Packham G: MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol 35: 339-347, 2009.
29. Vink SR, Lagerwerf S, Mesman E, et al: Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res 12: 1615-1622, 2006.
30. Momota H, Nerio E and Holland EC: Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas invivo. Cancer Res 65: 7429-7435, 2005.
31. Gills JJ and Dennis PA: Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11: 102-110, 2009.